Literature DB >> 25904378

Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience.

Lucia Masarova1, Mohamad Cherry2, Kate J Newberry1, Zeev Estrov1, Jorge E Cortes1, Hagop M Kantarjian1, Srdan Verstovsek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25904378      PMCID： PMC4712116          DOI： 10.3109/10428194.2015.1041392

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  5 in total

1.  Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.

Authors:  G Finazzi; M Ruggeri; F Rodeghiero; T Barbui
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

2.  Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.

Authors:  Henrik Frederiksen; Dóra Körmendiné Farkas; Christian Fynbo Christiansen; Hans Carl Hasselbalch; Henrik Toft Sørensen
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

3.  Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Alessandro M Vannucchi; Giovanna Masala; Elisabetta Antonioli; Maria Chiara Susini; Paola Guglielmelli; Lisa Pieri; Laura Maggi; Saverio Caini; Domenico Palli; Costanza Bogani; Vanessa Ponziani; Alessandro Pancrazzi; Francesco Annunziato; Alberto Bosi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-16       Impact factor: 4.254

4.  Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.

Authors:  Franca Radaelli; Francesco Onida; Francesca G Rossi; Vittorio R Zilioli; Mariangela Colombi; Patrizia Usardi; Rossella Calori; Alberto Zanella
Journal:  Hematology       Date:  2008-08       Impact factor: 2.269

5.  Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.

Authors:  Francesco Passamonti; Elisa Rumi; Ester Pungolino; Lucia Malabarba; Paola Bertazzoni; Marina Valentini; Ester Orlandi; Luca Arcaini; Ercole Brusamolino; Cristiana Pascutto; Mario Cazzola; Enrica Morra; Mario Lazzarino
Journal:  Am J Med       Date:  2004-11-15       Impact factor: 4.965
  5 in total
  9 in total

Review 1.  Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Loretta Nastoupil; Megan Dupuis; Lisa Zhou; Sherry Pierce; Keyur P Patel; Lucia Masarova; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2019-02-22       Impact factor: 22.113

2.  Therapy-related myelofibrosis does not appear to exist.

Authors:  Lucia Masarova; Gabriele Todisco; Taghi Manshouri; Kate J Newberry; Jorge E Cortes; Hagop M Kantarjian; Zeev Estrov; Srdan Verstovsek
Journal:  Blood Adv       Date:  2017-05-26

3.  Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.

Authors:  Cristina Santoro; Isabella Sperduti; Roberto Latagliata; Erminia Baldacci; Barbara Anaclerico; Giuseppe Avvisati; Massimo Breccia; Francesco Buccisano; Michele Cedrone; Giuseppe Cimino; Cinzia De Gregoris; Marianna De Muro; Ambra Di Veroli; Sabrina Leonetti Crescenzi; Marco Montanaro; Enrico Montefusco; Raffaele Porrini; Angela Rago; Antonio Spadea; Francesca Spirito; Nicoletta Villivà; Alesssandro Andriani; Giuliana Alimena; Maria Gabriella Mazzucconi
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

4.  Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges.

Authors:  Karan Seegobin; Bharatsinh Gharia; Satish Maharaj; Lara Zuberi
Journal:  Case Rep Hematol       Date:  2018-08-12

5.  Central Nervous System Lymphoma Harboring the JAK2 V617F Mutation That Developed after a 20-year History of Polycythemia Vera.

Authors:  Natsuki Kajikawa; Yoshimoto Seki; Takayuki Fujio; Yasushi Okoshi; Mitsuo Hori; Hitoaki Saito; Tatsuo Iijima; Hiroshi Kojima
Journal:  Intern Med       Date:  2018-07-06       Impact factor: 1.271

6.  Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Authors:  Barbara Mora; Elisa Rumi; Paola Guglielmelli; Daniela Barraco; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T Silver; Giulia Benevolo; Francesco Albano; Chiara Cavalloni; Daniela Pietra; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Alessandro Maria Vannucchi; Toni Giorgino; Francesco Passamonti
Journal:  Cancer Med       Date:  2019-06-07       Impact factor: 4.452

7.  A Case Report of BCR-ABL-JAK2-Positive Chronic Myeloid Leukemia with Complete Hematological and Major Molecular Response to Dasatinib.

Authors:  Elrazi Awadelkarim Hamid Ali; Susanna Al-Akiki; Mohamed A Yassin
Journal:  Case Rep Oncol       Date:  2021-04-15

8.  Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.

Authors:  Rohit Sekhri; Parvis Sadjadian; Tatjana Becker; Vera Kolatzki; Karlo Huenerbein; Raphael Meixner; Hannah Marchi; Rudolf Wallmann; Christiane Fuchs; Martin Griesshammer; Kai Wille
Journal:  Ann Hematol       Date:  2021-08-31       Impact factor: 3.673

9.  Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data.

Authors:  Arianna Ghirardi; Alessandra Carobbio; Arianna Masciulli; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-01-16       Impact factor: 11.037
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.